Topical aldose reductase inhibitor for correcting comeal endothelial changes in diabetic patients

26Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Background-Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. Method-Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. Results-Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. Conclusion-These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.

Cite

CITATION STYLE

APA

Ohguro, N., Matsuda, M., Ohashi, Y., & Fukuda, M. (1995). Topical aldose reductase inhibitor for correcting comeal endothelial changes in diabetic patients. British Journal of Ophthalmology, 79(12), 1074–1077. https://doi.org/10.1136/bjo.79.12.1074

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free